
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. has a promising outlook due to the anticipated 25%-30% increase in shares, supported by a 70% probability of achieving a base case scenario with a projected 15% rise. The company's pipeline features Claseprubart, which exhibits greater potency than its predecessor, riliprubart, suggesting a favorable efficacy profile that could enhance its market potential as the company advances to Part B of its clinical assessments. Additionally, the updated cash position of approximately $514 million at year-end 2025, along with revisions to the valuation model that raise the target from $46 to $55, further solidifies a positive financial outlook for Dianthus Therapeutics.
Bears say
Dianthus Therapeutics Inc. may face significant financial challenges due to its inability to secure adequate funds, which could hinder the advancement of its clinical pipeline. The reliance on successful fundraising raises concerns about liquidity and operational sustainability, especially as the company is still in the clinical stage. Additionally, potential setbacks in their interim results could further complicate their financial outlook and impede progress on developing their therapies.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares